Proteomic (N-terminal associations pro-B-type natriuretic of NT-proBNP peptide) in heart failure with preserved ejection fraction

Joe David Azzo, Marie Joe Dib, Loukas Zagkos, Lei Zhao, Zhaoqing Wang, Ching Pin Chang, Christina Ebert, Oday Salman, Sushrima Gan, Payman Zamani, Jordana B. Cohen, Vanessa van Empel, A. Mark Richards, Ali Javaheri, Douglas L. Mann, Ernst R. Rietzschel, Peter H. Schafer, Dietmar A. Seiffert, Dipender Gill, Stephen BurgessFrancisco Ramirez-Valle, David A. Gordon, Thomas P. Cappola, Julio A. Chirinos

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

BACKGROUND: NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels are variably elevated in heart failure with preserved ejection fraction (HFpEF), even in the presence of increased left ventricular filling pressures. NT-proBNP levels are prognostic in HFpEF and have been used as an inclusion criterion for several recent randomized clinical trials. However, the underlying biologic differences between HFpEF participants with high and low NT-proBNP levels remain to be fully understood. METHODS: We measured 4928 proteins using an aptamer-based proteomic assay (SOMAScan) in available plasma samples from 2 cohorts: (1) Participants with HFpEF enrolled in the PHFS (Penn Heart Failure Study; n=253); (2) TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) participants in the Americas (n=218). We assessed the relationship between SOMAScan-derived plasma NT-proBNP and levels of other proteins available in the SOMAScan assay version 4 using robust linear regression, with correction for multiple comparisons, followed by pathway analysis. RESULTS: NT-proBNP levels exhibited prominent proteome-wide associations in PHFS and TOPCAT cohorts. Proteins most strongly associated with NT-proBNP in both cohorts included SVEP1 (sushi, von Willebrand factor type-A, epidermal growth factor, and pentraxin domain containing 1; βTOPCAT=0.539; P<0.0001; βPHFS=0.516; P<0.0001) and ANGPT2 (angiopoietin 2; βTOPCAT=0.571; P<0.0001; βPHFS=0.459; P<0.0001). Canonical pathway analysis demonstrated consistent associations with multiple pathways related to fibrosis and inflammation. These included hepatic fibrosis and inhibition of matrix metalloproteases. Analyses using cut points corresponding to estimated quantitative concentrations of 360 pg/mL (and 480 pg/mL in atrial fibrillation) revealed similar proteomic associations. CONCLUSIONS: Circulating NT-proBNP levels exhibit prominent proteomic associations in HFpEF. Our findings suggest that higher NT-proBNP levels in HFpEF are a marker of fibrosis and inflammation. These findings will aid the interpretation of NT-proBNP levels in HFpEF and may guide the selection of participants in future HFpEF clinical trials.

Original languageEnglish
Pages (from-to)E011146
JournalCirculation: Heart Failure
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2024

Keywords

  • Biomarkers
  • Fibrosis
  • Heart failure
  • Inflammation
  • Proteomics

Fingerprint

Dive into the research topics of 'Proteomic (N-terminal associations pro-B-type natriuretic of NT-proBNP peptide) in heart failure with preserved ejection fraction'. Together they form a unique fingerprint.

Cite this